| Style | Citing Format |
|---|---|
| MLA | Zahednasab H, et al.. "Metalloproteinase 9 As a Biomarker of Progressive Multifocal Leukoencephalopathy Development in Multiple Sclerosis Patients Receiving Natalizumab." Annals of Neurology, vol. 82, no. 4, 2017, pp. 647-. |
| APA | Zahednasab H, Harirchian MH, Karampoor S, Keyvani H (2017). Metalloproteinase 9 As a Biomarker of Progressive Multifocal Leukoencephalopathy Development in Multiple Sclerosis Patients Receiving Natalizumab. Annals of Neurology, 82(4), 647-. |
| Chicago | Zahednasab H, Harirchian MH, Karampoor S, Keyvani H. "Metalloproteinase 9 As a Biomarker of Progressive Multifocal Leukoencephalopathy Development in Multiple Sclerosis Patients Receiving Natalizumab." Annals of Neurology 82, no. 4 (2017): 647-. |
| Harvard | Zahednasab H et al. (2017) 'Metalloproteinase 9 As a Biomarker of Progressive Multifocal Leukoencephalopathy Development in Multiple Sclerosis Patients Receiving Natalizumab', Annals of Neurology, 82(4), pp. 647-. |
| Vancouver | Zahednasab H, Harirchian MH, Karampoor S, Keyvani H. Metalloproteinase 9 As a Biomarker of Progressive Multifocal Leukoencephalopathy Development in Multiple Sclerosis Patients Receiving Natalizumab. Annals of Neurology. 2017;82(4):647-. |
| BibTex | @article{ author = {Zahednasab H and Harirchian MH and Karampoor S and Keyvani H}, title = {Metalloproteinase 9 As a Biomarker of Progressive Multifocal Leukoencephalopathy Development in Multiple Sclerosis Patients Receiving Natalizumab}, journal = {Annals of Neurology}, volume = {82}, number = {4}, pages = {647-}, year = {2017} } |
| RIS | TY - JOUR AU - Zahednasab H AU - Harirchian MH AU - Karampoor S AU - Keyvani H TI - Metalloproteinase 9 As a Biomarker of Progressive Multifocal Leukoencephalopathy Development in Multiple Sclerosis Patients Receiving Natalizumab JO - Annals of Neurology VL - 82 IS - 4 SP - 647 EP - PY - 2017 ER - |